We exist to improve the lives
of everyone affected by epilepsy

Trial finds cannabidiol may successfully reduce number of convulsive seizures in children and young adults with Dravet syndrome

25 May 2017

A new study has found that cannabidiol could be an effective treatment for people with Dravet syndrome.

Cannabidiol comes from the cannabis plant. It does not contain the part of cannabis that gives a ‘high’ – the psychoactive part.

The researchers, Dr Devinsky and colleagues, wanted to look at whether cannabidiol could be used to treat seizures in Dravet syndrome. This condition is a rare and severe form of epilepsy which is difficult to treat with epilepsy medicines.

The study was carried out on 120 children and young adults (aged 2-18 years) with Dravet syndrome across 23 centres across Europe and the US. They all had seizures not responding to epilepsy medicines. The children were randomly chosen to either be given cannabidiol or a placebo – a similar treatment but which doesn’t have an effect on health. The children were studied over 14 weeks.

The study found that cannabidiol reduced the number of children’s convulsive seizures from around 12 a month on average, to about 6. The group who had placebo treatment saw hardly any fall in seizure numbers. About 2 in 5 children had the number of their convulsive seizures fall by half. According to the study, for the majority of children and young adults in the group taking cannabidiol, overall health improved.

However, while cannabidiol was successful in reducing the number of convulsive seizures, it did not have much of an effect on other types of seizures, the study found. A few side-effects were linked to cannabidiol, including diarrhoea, vomiting, tiredness, drowsiness and fever.

Professor Helen Cross from Great Ormond Street Hospital in London, who was one of the researchers on the study, said: “The data are really exciting. They show cannabidiol to have significant benefit in [convulsive] seizure control in Dravet syndrome, a particularly complex epilepsy syndrome with a poor prognosis for seizure control and neurodevelopmental outcome. It is a major step forward for this population.”

Simon Wigglesworth, deputy chief executive of Epilepsy Action said: “We welcome this exciting new research showing positive results in reducing [convulsive] seizures for patients with Dravet syndrome. We hope this will lead to this new medicine being made available to patients in the not-too-distant future.

“Cannabidiol is the non-psychoactive part of cannabis which may have anti-epileptic properties. There has recently been encouraging research findings in this area, which could enable people with rare forms of epilepsy to gain better seizure control. The study focused on Dravet syndrome which occurs in between 1-2 in every 500 children with epilepsy. However, it is one of the epilepsy syndromes which is most resistant to epilepsy medicines.”

The research is published in The New England Journal of Medicine.

There is more information on cannabis-based medicines and on Dravet syndrome on the Epilepsy Action website.

 

You may also be interested in...

Cannabis oil prescribed on NHS in ‘first case of its kind’ in the UK

The medicine cannabis oil has been prescribed to a young boy with epilepsy on the NHS. Reports have called this the “first case of its kind” in the UK.

There are no comments yet. Be the first to comment...

Question about your epilepsy?

Use our email helpline service -- your question will be sent directly to our trained helpline advisors who will reply to you. If you post a question about your epilepsy as a comment on a page, it may not be replied to so please use the email helpline service.

Want to talk to other people with epilepsy?

Take a look at forum4e our online community for people with epilepsy. Anyone with epilepsy over the age of 16 can join, from anywhere in the world.

Comment about this page?

We welcome feedback on the content of our website. If you have any comments about the page you were reading, then please complete the form below.

All comments are reviewed by a moderator before appearing on the site. Once the comment appears, your name and comment will be seen by other visitors to the site. Comments will be edited or deleted if they are offensive, libellous, slanderous, abusive, commercial or irrelevant. Comments may also be edited or deleted if they are not relevant to the page on which they are entered.

By making a comment through the website, you allow us to use the comment in our publicity without using your name. If we would like to use your name, we will email you to get your permission.

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
By submitting this form, you accept the Mollom privacy policy.